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Abstract 
Androgenetic alopecia, or male/female pattern baldness, is the most common type of progressive hair 
loss disorder. The aim of this paper is to review recent advances in non-surgical treatments for 
androgenetic alopecia and identify the most effective treatments. A network meta-analysis (NMA) was 
conducted of the available literature of the six most common non-surgical treatment options for treating 
androgenetic alopecia in both men and women; dutasteride 0.5mg, finasteride 1mg, low level laser 
therapy (LLLT), minoxidil 2%, minoxidil 5% and platelet rich plasma (PRP). Seventy-eight studies met 
the inclusion criteria and twenty-two studies had the data necessary for a network meta-analysis. 
Relative effects show LLLT as the superior treatment. Relative effects show PRP, finasteride 1 mg 
(male), finasteride 1 mg (female), minoxidil 5%, minoxidil 2% and dutasteride (male) are approximately 
equivalent in mean change hair count following treatment. Minoxidil 5% and minoxidil 2% reported the 
most drug-related adverse events (n=45 and n=23, respectively). The quality of evidence of minoxidil 
2% vs. minoxidil 5% was high; minoxidil 5% vs. placebo was moderate; dutasteride (male) vs. placebo, 
finasteride (female) vs placebo, minoxidil 2% vs. placebo, minoxidil 5% vs. LLLT was low and finasteride 
(male) vs. placebo, LLLT vs. sham, PRP vs. placebo, finasteride vs. minoxidil 2% was very low. Results 
of this NMA indicate the emergence of novel, non- hormonal therapies as effective treatments for hair 
loss; however, the quality of evidence is generally low. High quality randomized controlled trials and 
head to head trials are required to support these findings and aid in the development of more 
standardized protocols, particularly for PRP. Regardless, this analysis may aid physicians in clinical 
decision making and highlight the variety of non-surgical hair restoration options for patients. 
 
 
Summary 
Androgenetic alopecia (AGA) is a common hair loss condition that is characterized by the miniaturization 
of hair follicles in the frontal and parietal regions of the scalp1. This miniaturization may be driven by the 
conversion of testosterone to dihydrotestosterone (DHT) by 5-α reductase or alterations in the androgen 
receptor gene2–4. Treatments, such as hormone and biological response modifiers, have been used to 
combat this miniaturization and stabilize hair loss in AGA patients5,6. Hormone response modifiers, such 
as finasteride, promote hair growth by inhibiting type II 5-α reductase. This inhibition blocks the 
conversion of testosterone to DHT, promoting cell survival and proliferation5,7. Although the exact 
mechanism for biological response modifiers, such as minoxidil, are not yet known, minoxidil is thought 
to promote hair growth through vasodilation and/or stimulation of hair follicles into the growth phase8–11. 
As an alternative to traditional therapies, other non-surgical treatments such as platelet-rich plasma 
(PRP) and low level laser therapy (LLLT) have also shown promise12. Through isolating platelets found 
in whole blood, growth factors can be concentrated and injected into the hair follicle and surrounding 
area. Evidence has suggested that these concentrated growth factors can promote angiogenesis and 
vascularization, accelerate hair regrowth, increase the duration of the hair growth phase and stimulate 
catagen development13–17. Alternatively, through photobiomodulation, red light emitted by LLLT devices 
may encourage hair growth by accelerating keratinocyte and fibroblast mitosis, inhibiting nitric oxide and 
reducing inflammation18–21 (Figure 1a, 1b, 1c and 1d). 
 
Due to the limited number of head-to-head clinical trials and the limitations of published meta-analyses 
(e.g., comparisons limited to 2 treatments), comparing the efficacies of non-surgical treatments is 
predominately qualitative22. Quantitative comparisons of the efficacy of non-surgical AGA treatments 
that have not been directly compared in head-to-head trials would be a valuable tool for both clinicians 
and hair restoration surgeons, potentially aiding treatment decisions and influencing patient outcomes. 
To address this literature gap a network meta-analysis was conducted using randomized control trials 
(RCTs) of six main non-surgical AGA treatments; finasteride, dutasteride, minoxidil (2% and 5%), PRP 
and LLLT. Using placebo as a common comparator, the efficacy of non-surgical treatments was 
indirectly and directly compared, using the mean difference in hair count from baseline as the outcome 
measure23. 
 
 
Materials and methods 
Systematic review 
This systematic review and meta-analysis was conducted in agreement with the 2015 modified 32-item 
PRISMA extension statement for network meta-analysis (NMA)24. Studies were eligible for inclusion if 
they were randomized, placebo-controlled or head-to-head trials of non- surgical treatment for 
androgenetic alopecia published in English. Combination therapies were not included. 
  
Details regarding the databases searched and study identification for this review are provided in 
Appendix S1 (see Supplementary Material). Treatment effects were evaluated based on the efficacy 
rates and safety parameters reported in the randomized trials identified during the systematic review. 
Hair count was selected as our primary outcome and the end point selected was the most commonly 
reported time per treatment regime (Table S1). Details regarding the quality of evidence and risk-of-bias 
assessment for this review are provided in Appendix S125. Data extracted from trials were combined by 
a random-effects model, with effect sizes expressed as difference of means of achieving each outcome 
in the treatment arm versus the control arm. Total effect size was calculated by the Mantel-Haenszel 
method. Heterogeneity was evaluated with I2 calculations. Statistical analysis was performed with 
RevMan 5.3 with two- tailed P-values < 0.05 considered significant. Forest plots and funnel plots were 
obtained for each outcome analyzed and included in the supplementary material. 
 
Network meta-analysis 
NMA was used to make mixed comparisons among the therapeutic options and to rank treatments, 
using the program Aggregate Data Drug Information Software (ADDIS) version 1.16.8 program26. 
Inconsistency between direct and indirect evidence in the network was analyzed using difference of 
means. A P-value < 0.05 indicated significant inconsistency between the direct and indirect evidence in 
the network. 
 
Results 
Results of the search 
There were 10,484 records identified by our literature search (PubMed, Scopus, Embase, Cochrane 
Libraries, ClinicalTrials.gov and Medline) (Figure 2). Seventy-eight27–45,45–48,17,49–103 met the inclusion 
criteria and were included in the quantitative analysis. A total of 15,888 participants (88.1% male) were 
included with an average age 36.0±7.3 (Table 1). 
 
Twenty-two studies28,32,37,45,46,48,52,61,64,65,68,69,72,80,85,84,81,93,98,101–103 of the seventy-eight included in the 
quantitative analysis had the data necessary for a network meta-analysis. The included trials had 2,421 
randomized participants, which were 64.2% male. The average age of participants was 37.7±7.1. The 
severity of disease was most commonly IV (n=273) and III vertex (n=497) on the Norwood-Hamilton 
Classification and II (n=381) on the Ludwig/Savin Scale. Detailed information for all the studies included 
in the network meta-analysis is presented in Table 1. A network graph summarizing the comparisons is 
provided in Figure 3.
 
 
Risk of bias 
None of the included studies were judged to be low-risk across all six domains (Figure S1). With the 
exception of one domain (selective reporting), Hillmann et al.52, was the only study to have a low-risk 
judgement across all domains. Four studies64,65,69,72 (20%) were judged as low-risk on all but two 
domains. Detection bias (blinding of the outcome assessment) had the lowest risk of bias (64% of papers 
reported low risk). Incomplete outcome data (attrition bias – not reporting all participants and/or reasons 
for discontinuation) was the domain with the largest number of studies (50%) to be judged as high-risk, 
followed closely by selective reporting (reporting bias) (27%). Price et al.84, was the only study to have 
an unclear judgement across all domains. 
 
Quality of evidence 
When considering mean hair count, evidence for treatment efficacy was generally low quality according 
to GRADEpro assessment. In treatment versus placebo studies: LLLT, PRP and finasteride (male) 
reported very low quality of evidence, finasteride (female), dutasteride (male) and minoxidil 2% had low 
quality evidence and minoxidil 5% had moderate quality evidence. When considering the treatment 
versus treatment: finasteride (male) versus minoxidil 2% had very low level quality of evidence, minoxidil 
5% versus LLLT had low level of evidence and minoxidil 2% versus minoxidil 5% had high quality of 
evidence. Evidence was downgraded initially due to high risk of bias. Additionally, LLLT studies showed 
considerable inconsistency with high heterogeneity (I2=93%). Dutasteride (male), LLLT, PRP, 
finasteride (male) vs minoxidil 2%, and minoxidil 5% vs LLLT analyzed less than 400 participants which 
contributed to the imprecision of the evidence. 
 
Efficacy of direct comparisons 
Meta-analysis of direct pair-wise comparisons showed that all non-surgical treatments exhibited greater 
efficacy over placebo with response to mean change hair count (Table 2, Figure S2). LLLT was the most 
effective treatment (mean difference [95% CI]: 66.70 [24.09, 109.31]), followed by PRP (23.51 [9.91, 
37.11]) as demonstrated by their mean change hair count. Finasteride (female) was the least effective 
treatment (-1.93 [-5.27, 1.42]). Minoxidil 5% had the most drug- related adverse events (n=45) whereas 
PRP had the least (n=0), Table 1 and 5. Direct comparisons of treatments showed that finasteride was 
favoured over minoxidil 2% (8.10 [3.80, 12.40], minoxidil 5% was favoured over minoxidil 2% (4.69 [1.35, 
8.04]) and LLLT was favoured over minoxidil 5% (1.53 [22.64, 25.70]) (Table 2, Figure S2-S5). 
 
Results of the network meta-analysis indicate that the mean difference of LLLT is superior to all 
treatments. Additionally, finasteride (male) and minoxidil 2% indicated greater efficacy over placebo 
(21.140 [7.454, 35.465] and 16.615 [1.885, 33.023]) (Table 3). Otherwise relative effects showed that 
PRP, finasteride (male), finasteride (female), minoxidil 5%, minoxidil 2% and dutasteride (male) are 
approximately equivalent in mean change hair count following treatment (Table 3). 
 
Inconsistency analysis 
The indirect comparison of minoxidil 5% vs placebo, minoxidil 5% vs minoxidil 2%, minoxidil 5% vs LLLT 
and finasteride (male) vs placebo showed a treatment effect larger than the direct evidence. The indirect 
comparisons of minoxidil 2% vs placebo, LLLT vs sham and minoxidil 2% vs finasteride (male), showed 
a treatment effect smaller than the direct evidence (Table 4). 
 
Model Fit 
The mean deviance under the current model, relative to the deviance under a saturated model is referred 
to as the residual deviance. The residual deviance of our model was 50.5, the leverage (the influence 
of each data point) was 42.8 and the Deviance Information Criterion (model fit versus model complexity) 
was 93.3. The number of data points on which the fit is based was 46 (Figure S6). 
 
Ranking of treatments by efficacy 
Rank probabilities encode the probability for each treatment to be the best, second best, third best, etc. 
The probability that LLLT will be the most effective treatment option (rank 1) for our data is 92%, followed 
by PRP (5.2%). The probability that PRP will be the second most effective treatment option (rank 2) is 
33.8%, followed by minoxidil 5% (21.8%). The probability that finasteride (male) will be the third most 
effective treatment option is 29.3%, and so on (Figure 4). 
 
We used the surface under the cumulative ranking (SUCRA) probabilities to assess the efficacy of 
treatments. SUCRA expresses a percentage representing the efficacy of every intervention compared 
with a control. It is used to provide a hierarchy of the treatments and accounts both for the location and 
the variance of all relative treatment effects. A higher SUCRA score indicates a higher probability to be 
effective. The SUCRA scores demonstrate LLLT with the highest SUCRA (98.7%) followed by PRP, 
finasteride (male) and minoxidil 5% with similar scores (64.3%, 62.5% and 62.4%; respectively). 
Minoxidil 2%, dutasteride (male) and finasteride (female) report lower scores (51.0%, 32.9% and 14.4%; 
respectively) (Table 5). 
 
Discussion 
This network meta-analysis (NMA) compared the relative efficacy of finasteride, minoxidil 2% and 5%, 
low level laser therapy and platelet-rich plasma therapy in the treatment of androgenetic alopecia. 
Results indicate that the mean difference of LLLT is greater compared to all treatments. Additionally 
relative effects show PRP, finasteride 1 mg, minoxidil 5%, minoxidil 2% and dutasteride are 
approximately equivalent in mean change hair count following treatment. Minoxidil 5% and 2% reported 
the greatest amount of adverse events. 
 
While results of this NMA indicate LLLT produced the largest increase in hair count, the quality of 
evidence is very low as determined by the risk of bias assessment. Further, these trials may require 
further scrutiny, as all five trials included in the NMA report funding and support from the device 
manufacturer or funding and/or affiliation of the author with the manufacturer. Nonetheless, these trials 
met the strict inclusion criteria of this NMA and analysis indicates LLLT is a highly effective treatment 
option. 
PRP is also an effective treatment for AGA. However, quality of evidence of PRP is “very low” according 
to GRADEpro assessment. There are few randomized controlled trials examining the efficacy of PRP in 
AGA. Half head studies are common in the literature, however, this design may be considered 
problematic as each patient contributes to the treatment and control arm of the study. There is also a 
high degree of variability in study design among PRP trials. Studies have reported treatment 
administration weekly, monthly, and bimonthly and range in the total number of treatment sessions. 
Further, unlike oral or topical formulations such as finasteride or minoxidil, which are prescribed at 
standard doses, there is significant variability in the preparation and administration of PRP. Individual 
preparation systems and added activators can influence the concentration of growth factors17. Coupled 
to variability in frequency and volume of injections, this creates substantial differences in dosing across 
studies. We included trials in which activated PRP was administered. 
 
Finasteride 1 mg and minoxidil 5% demonstrated similar efficacy. As such, other factors including the 
risk of adverse events (AEs) may contribute to clinical decision making. AEs reported with finasteride 
use are predominantly related to sexual dysfunction. Decreased libido, erectile dysfunction, and sexual 
adverse events are reported in several of the trials included in this NMA. The prevalence of sexual 
adverse events associated with finasteride use is widely discussed in the literature. We have previously 
demonstrated an increase in reports of sexual dysfunction with finasteride as the primary suspect in the 
U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)104. Others report 
persistent sexual dysfunction up to one year after cessation of finasteride treatment105. The side effects 
of minoxidil 5% ranged from dermatologic in nature, such as hypertrichosis, and burning and itching of 
the skin, to cardiovascular AEs. The mechanism of action of minoxidil may contribute to the 
cardiovascular AEs, as it is a vasodilator. While the results of this NMA indicate finasteride 1 mg and 
minoxidil 5% demonstrate similar efficacy, considering the AEs associated with each treatment may aid 
in clinical decision making. 
 
We included data for male and female participants from trials for minoxidil, LLLT and PRP. However, 
we separated the males and females for finasteride and dutasteride as we felt the results would have 
been skewed if we combined them. There were no studies reporting females taking dutasteride. In AGA, 
dihydrotestosterone (DHT) binding to androgen receptors in the scalp contributes to hair loss. DHT is 
formed by enzymatic conversion of testosterone to DHT by 5α- reductase, and these enzymes are 
inhibited by finasteride and dutasteride. Given the hormonal mechanism of action of 5α-reductase 
inhibitors, they are not approved for the treatment of hair loss in female patients. Finasteride has been 
associated with negative effects on the fetus as well as menstrual and endometrial abnormalities among 
others106. Dutasteride is a dual 5α-reductase inhibitor, which is approved for use in the treatment of 
benign prostatic hyperplasia and is used off- label for hair loss. Therefore, data for female participants 
was separated from the males. 
 
A potential limitation of this analysis was the use of hair count as a primary outcome measure. AGA 
treatment efficacy can be determined with a variety of different assessments. Expert assessment of 
global photographs, hair counts using phototrichogram and manual hair counts using clippings have all 
been reported in the literature. Our rationale for selecting hair count was twofold: first, this is a more 
quantitative measure than global photographic assessment; studies reporting only global photographic 
assessment were not included. Second, some studies reported hair density (the number of hairs per 
predefined area). It is possible to convert hair count to hair density when provided a target area, however 
it is not possible if the area is not specified. Therefore, in order to maximize the number of included trials 
in this NMA we selected hair count as our primary outcome measure. Unfortunately, this may be a 
limiting factor, as larger target areas would in theory have greater hair counts. This presents a point of 
consideration in the development and initiation of new trials. The use of a consistent outcome measure 
may aid in the comparison of treatment efficacy across many different treatments for hair loss or other 
dermatological conditions. 
 
Another limitation to this study is the comparison of drugs with different routes of administration. Oral 
(finasteride), topical (LLLT, minoxidil) and intradermal injection (PRP) were all compared in this NMA. 
These treatments function through unique mechanisms of action and may have different metabolism 
and durations of effect. Despite this, all treatments compared in this analysis are FDA approved for use 
in the treatment of AGA. Therefore, these findings are relevant to clinicians and patients in the 
development of a treatment plan. 
 
In addition to these limitations, the measurement of efficacy for AGA treatments has not yet been 
standardized; leading to multiple units of analysis reported across studies and therapies (e.g. hair 
density, hair count, hair shedding etc.). Furthermore, of the 20 studies included in the analysis, only six 
(30%) did not have obvious links to industry28,38,45,80,93,102. Most studies included in the analysis (14/20 = 
70%) were supported or funded by invested parties (e.g., drug manufacture, patent owner, etc.). This 
may have contributed to the high number of studies judged to have a high risk of reporting bias and/or 
attrition bias. Industry funding for studies is often inevitable and appreciated; high-quality trials with low 
risk of bias counters perceptions of conflicted interests. 
 
Systematic reviews as well as clinical trials must be designed rigorously in order to ensure the validity 
of the finding of the network meta-analysis. Interpreting the results of a NMA can prove challenging for 
the non-expert statistician. One of the most commonly misinterpreted parts of a NMA is the probability 
rankings. Ranking done in medical statistics will always depend on the criteria; one treatment may be 
best for efficacy but worse for long term safety. A risk subsists that one may incorrectly accentuate the 
probabilities as being clinically useful. That is why it is important to consider the numerical values of the 
rankings themselves, not only their probability ranks. The SUCRA scores also can be misleading as the 
SUCRA is most meaningful when the difference in preference between successive ranks remains the 
same across the entire ranking scale107. Our data does not have such interval scaling, thus weakening 
the SUCRA evidence. For clinical application, greater emphasis on the treatment effects and their 
uncertainty are crucial. As new trials are published, the network will expand and treatment rankings may 
change considerably. Consideration should also be issued to cost and a clinician’s familiarity with use 
of a particular treatment. 
 
In summary, results of this NMA indicate the emergence of more novel, non-hormonal therapies as 
effective treatments for hair loss. Further randomized controlled trials and head to head trials limiting 
risk of bias are required to support these findings and aid in the development of more standardized 
protocols, particularly for PRP. The data may provide guidance to physicians when counselling patients 
with AGA regarding non-surgical options. 
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Table 2 Direct comparison of each non-surgical treatment included in the network 
 
Treatment 1 Treatment 2 Mean change hair 
count 
Number of trials making 
direct comparison 
Treatment vs. Placebo 
LLLT Placebo 66.70 [24.26, 109.13] 5 
PRP Placebo  23.51 [9.91, 37.11] 2 
Finasteride 1 mg (male) Placebo 17.37 [11.67, 23.07] 5 
Minoxidil 5% Placebo 14.24 [10.72, 17.75] 3 
Minoxidil 2% Placebo 11.51 [5.34, 17.67] 4 
Dutasteride 0.5 mg (male) Placebo 7.50 [0.76, 14.24] 1 
Finasteride 1 mg (female) Placebo −ϭ.9ϯ [−ϱ.Ϯϳ, ϭ.ϰϮ] 2 
Treatment vs. Treatment 
Finasteride 1 mg (male) Minoxidil 2% 8.10 [3.80, 12.40] 1 
Minoxidil 2% Minoxidil 5% 4.69 [1.35, 8.04] 2 
Minoxidil 5% LLLT ϭ.ϱϯ [−ϮϮ.ϲϰ, Ϯϱ.ϳϬ] 1 
 
 
 
 
 
  
  
  
  
  
  
  
Figure 1a. Working hypotheses of anti-androgens in AGA. 
 
 
  
Figure 1b. Working hypotheses of minoxidil in AGA. 
 
 
  
Figure 1c. Working hypotheses of PRP in AGA. 
 
 
  
Figure 1d. Working hypotheses of LLLT in AGA. 
 
 
  
 Figure 2. Summary of literature search for RCTs. 
 
 
 
  
Figure 3. Network graph. The network graph shows the evidence network for all selected interventions. 
The size of an intervention's circle reflects the total number of participants for that intervention. Lines 
signify that interventions are connected through at least one study, with thicker lines indicating more 
connecting studies. 
 
 
 
  
Figure 4. Bar plots for the ranking probabilities of competing non-surgical treatments for AGA. On the 
horizontal axis is the possible rank of each treatment (from best to worst according to the outcome). The 
size of each bar corresponds to the probability of each treatment to be at a specific rank. 
 
 
 
